Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Key Highlights
- ➤Palvella management to participate in Chardan healthcare conference fireside chat October 20, 2026
- ➤QTORIN rapamycin targets three rare vascular and skin conditions
- ➤QTORIN pitavastatin is being developed for disseminated superficial actinic porokeratosis
- ➤Both QTORIN candidates remain investigational and lack FDA approval
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that members of its management team will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 1:45 p.m. ET.
A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay will be available for approximately 90 days following the event.
Get started
Create a free account to read the full story.